Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISAL 2019 | Bob Löwenberg’s perspective on CAR-T and immunotherapy for AML

Bob Löwenberg • 24 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Antibodies CAR-T

Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, discusses his thoughts on CAR T-cell therapy and other immuno-oncology treatments for acute myeloid leukemia (AML). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Bob Löwenberg

Azacitidine maintance to improve DFS in elderly AML: HOVON-97 results 1:02
Azacitidine maintance to improve DFS in elderly AML: HOVON-97 results
Bob Löwenberg • 24 Feb 2019
Developments in newly diagnosed AML therapy in Europe: inspiring cooperation for tailored treatment 3:46
Developments in newly diagnosed AML therapy in Europe: inspiring cooperation for tailored treatment
Bob Löwenberg • 24 Feb 2019
How can we tackle treatment failure in ALL? 3:18
How can we tackle treatment failure in ALL?
Bob Löwenberg • 16 Apr 2018
The molecular heterogeneity of acute myeloid leukemia (AML) – new data and implications 4:57
The molecular heterogeneity of acute myeloid leukemia (AML) – new data and implications
Bob Löwenberg • 19 Feb 2017

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals